BCL2 and acute myeloid leukemia: Combination therapy with venetoclax (a BCL-2 selective inhibitor) and a hypomethylating agent or low-dose cytarabine has improved treatment outcomes in elderly or unfit AML patients (DiNardo et al., 2019; Wei et al., 2019; Maiti et al., 2021).